Actively Recruiting
CArdioMetabolism and Atherosclerotic PlaqUe progreSsion
Led by Ruijin Hospital · Updated on 2024-08-06
3000
Participants Needed
1
Research Sites
469 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Systematic metabolic diseases are closely related to prevalence and progression of atherosclerosis. This prospective cohort consecutively enrolls patients with coronary artery disease compliacted with metabolic abnormalities such as diabtetes, prediabetes, obesity, chronic kidney disease and hyperuricemia.
CONDITIONS
Official Title
CArdioMetabolism and Atherosclerotic PlaqUe progreSsion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years
- Established coronary artery disease or metabolic disorders including:
- Type 2 diabetes diagnosed by HbA1c ≥ 6.5%, fasting plasma glucose ≥ 7.0 mmol/l (confirmed), 2h plasma glucose ≥ 11.1 mmol/l during OGTT, or receiving glucose-lowering agents
- Prediabetes
- Obesity
- Chronic kidney disease
- Hyperuricemia
- Dyslipidemia
You will not qualify if you...
- Severe liver failure (Child-Pugh grade B to C)
- Severe anemia (hemoglobin < 60g/L)
- Familial hypercholesterolemia
- Active malignant tumor
- Active autoimmune diseases on corticosteroids
- Acute or chronic infection
- Life expectancy less than 1 year
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China, 200025
Actively Recruiting
Research Team
X
Xiaoqun Wang, M.D., Ph.D.
CONTACT
S
Shuo Feng, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here